PhRMA Appointed Eric Cantor as President and CEO
The former House majority leader will lead the trade group as it faces increased federal scrutiny.
Updated on Sept. 29, 2026 in People
Live Poll
Do you trust that pharmaceutical companies are pricing their prescription drugs fairly?
PhRMA has named former U.S. House majority leader Eric Cantor as its new president and CEO. Cantor succeeds Steve Ubl, who led the biopharmaceutical industry trade association for 11 years.
Why it matters
The appointment comes as industry leaders prepare for potential shifts in federal oversight following the November 2026 midterms. Democrats, who are expected to take the House, have signaled intentions to scrutinize pharmaceutical company pricing deals.
Eric Cantor, 63, takes over as president and CEO of the trade group representing the biopharmaceutical industry. This follows the 11-year leadership tenure of outgoing executive Steve Ubl.
The players
Eric Cantor
A former U.S. House majority leader and financial executive who previously served as managing director at Moelis & Company.
PhRMA
The primary trade association representing the biopharmaceutical industry in federal policy and advocacy efforts.
Steve Ubl
The outgoing executive who served as president and CEO of PhRMA for 11 years.
The details
Cantor moves to the top lobbying role for the pharmaceutical sector after serving as vice chair and managing director at Moelis & Company. His transition follows an April 2026 announcement by Ubl that he intended to step down. The trade group is positioning itself for a period of potential political tension as analysts project a change in control of the House of Representatives.
Timeline
Cantor served in the U.S. House from 2000 to 2014.
Cantor served as House majority leader from 2011 to 2014.
Steve Ubl announced plans to step down in April 2026.
PhRMA announced Cantor as president and CEO on September 29, 2026.
The U.S. midterm elections are scheduled for November 3, 2026.
Market Landscape
The appointment signals a strategic move toward heavy policy-focused leadership for the pharmaceutical trade group. It aligns the association with the political dynamics that defined the 2011-2014 period of Cantor's service as House majority leader.
Operators should monitor federal legislative calendars closely following the November 3, 2026, midterm elections for potential changes in drug-pricing oversight. If political shifts impact pharmaceutical cost structures, these changes will likely ripple through supplier and retail pricing.
The takeaway
The move suggests the industry is prioritizing legislative navigation over other strategic focuses for the coming term. Business leaders should track potential upcoming Congressional committee hearings regarding pharmaceutical pricing as a leading indicator for industry regulatory risk.
Further reading
For more on shifts in the industry's influence, see our People section.
Source note: This article includes information reported by Axios.
Live Poll
Do you trust that pharmaceutical companies are pricing their prescription drugs fairly?
